# Andrew Wu

> Andrew Wu is the Singapore-based co-founder and CEO of Mesh Bio. A UCL-trained biochemical engineer with a bachelor’s degree and PhD, he previously served as technical director at Cordlife, held senior management and COO roles at Clearbridge Biomedics, and became chief product officer of Clearbridge Health. He co-founded Mesh Bio in 2018; the company subsequently joined Startup Creasphere, raised seed and Series A funding, and won an Emerging Enterprise Award in 2025.

- **Role:** Co-Founder and CEO at Mesh Bio
- **Organizations:** Mesh Bio, Clearbridge Biomedics (now Biolidics), Clearbridge Health, Cordlife Limited (later Life Corporation Limited)
- **Education:** Bachelor of Engineering in Biochemical Engineering, University College London, PhD in Biochemical Engineering, University College London
- **Known for:** Helped develop and commercialise the ClearCell FX System from a laboratory prototype at Clearbridge Biomedics., Oversaw Cordlife laboratory operations in five regional markets., Co-founded Mesh Bio in 2018.

## Career timeline

- **2003–2007** — Completed PhD studies in biochemical engineering at University College London, according to his ORCID record.
- **2007–2011** — Technical director at Cordlife Limited, overseeing laboratory operations across five regional markets.
- **2011–2016** — Held senior management positions at Clearbridge Biomedics.
- **2016–2017** — Chief operating officer of Clearbridge Biomedics, working on partnerships and international distribution.
- **2017** — Appointed chief product officer of Clearbridge Health in June.
- **2018** — Co-founded Mesh Bio; ORCID dates his co-founder and CEO role to June 2018.
- **2019** — Mesh Bio selected for Startup Creasphere Batch 3 in Munich.
- **2021** — Mesh Bio announced US$1.8 million in seed funding on 10 March.
- **2023** — Signed a partnership MoU with Pramita; Mesh Bio announced an East Ventures investment in October.
- **2024** — Mesh Bio announced a US$3.5 million Series A led by East Ventures on 30 January; selected for Forbes Asia 100 to Watch 2024.
- **2025** — Welcomed adviser Adrian Chua as COO; Mesh Bio won an Emerging Enterprise Award.
- **2026** — Mesh Bio listed in the Endless Frontier Labs Frontiers 2026 showcase in New York on 7 May.

## Achievements

- Helped develop and commercialise the ClearCell FX System from a laboratory prototype at Clearbridge Biomedics.
- Oversaw Cordlife laboratory operations in five regional markets.
- Co-founded Mesh Bio in 2018.
- Mesh Bio secured US$1.8 million seed funding in 2021 and US$3.5 million Series A funding in 2024.
- Mesh Bio selected for Forbes Asia 100 to Watch 2024.
- Mesh Bio won an Emerging Enterprise Award in 2025.

## Latest updates

- **2026-05** — Mesh Bio appeared in the Frontiers 2026 showcase directory for the 7 May New York event, listing Wu as CEO and co-founder.
- **2026-01** — Mesh Bio shared Wu’s MONEY FM appearance; in a comment, he credited the team’s work behind the interview.
- **2025-11** — Mesh Bio was named an Emerging Enterprise Award winner.

## Links

- Website: https://www.meshbio.com/team/andrew-wu
- LinkedIn: https://www.linkedin.com/in/andrewwu-healthtech/

---

Profile page: https://yespress.io/andrew-wu
Published by YesPress — https://yespress.io
Last updated: 2026-10-21